RecruitingNot ApplicableNCT05828446

Improving Hepatocellular Carcinoma Screening

Prospective Comparison of Diagnostic Performance and Cost-effectiveness of US and Abbreviated MRI for Hepatocellular Carcinoma Screening

Sponsor

Naik Vietti Violi

Enrollment

330 participants

Start Date

Apr 1, 2023

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma Magnetic Resonance Imaging Screening Contrast-enhanced US

Summary

This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI. Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a new type of liver scan (MRI with contrast) can detect liver cancer (hepatocellular carcinoma, or HCC) earlier and more accurately in people with chronic liver disease who need regular monitoring, compared to the standard ultrasound-based screening. **You may be eligible if...** - You are an adult with chronic liver disease - Your doctor recommends regular HCC screening based on European liver disease guidelines - You have signed informed consent **You may NOT be eligible if...** - You have a previous history of liver cancer or another cancer - You have had a previous suspicious liver lesion categorized as LI-RADS 4, 5, or M on imaging - You have had a liver transplant - You are pregnant - You have a contraindication to MRI (e.g., certain metal implants) or to MRI contrast agents Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.